S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
KROS · Keros Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Keros Therapeutics Inc (KROS)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$11.17
-0.23
(-2.02%)
● At close: October 21 at 4:00:00 PM EDT
DAY'S RANGE
$11.17
$11.14
$11.68
52-WEEK RANGE
$11.17
$9.69
$22.55
What's happening
- KROS is down 2.02% today, trading at $11.17. — Live quote
- Volume today (10,525) is well below its 3-month average of 223,750. (Finnhub fundamentals)
- Reports earnings on 2026-11-11 (after market close), 20 days away. (Finnhub earnings calendar)
- Last quarter's EPS missed estimates: $-1.45 actual vs. $-1.37 estimated (-6.1%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 3
Buy 6
Hold 4
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
KROS
-44.01%
vs S&P 500
-56.79%
1-YEAR RETURN
KROS
-24.95%
vs S&P 500
-39.51%
6-MONTH RETURN
KROS
-2.73%
3-MONTH RETURN
KROS
+7.85%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-1.45
Est. $-1.37
MISS -6.1%
2026-04-26 (Q1 2026)
$-1.21
Est. $-1.04
MISS -16.0%
2026-01-26 (Q4 2025)
$-0.86
Est. $-0.64
MISS -34.1%
2025-10-26 (Q3 2025)
$-0.18
Est. $-1.07
BEAT +83.1%
Valuation Measures & Ratios
Enterprise Value4-$36.1M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)6.67
Price / Book70.81
EV4 / Revenue-1.09
EV4 / EBITDA-0.52
Profit Margin-256.60%
Operating Margin-332.55%
Return on Equity (ROE8)-21.40%
Return on Assets (ROA9)-19.79%
Avg Volume (3M)223,750
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $211.7M | $216.5M | $639.8M | $539.4M | $415.6M |
| P/E | -2.34 | 2.50 | 11.12 | 27.60 | 58.34 |
| Price/Sales | 6.55 | 0.89 | 2.63 | 2.35 | 1.97 |
| Price/Book | 0.81 | 0.76 | 0.91 | 0.76 | 0.57 |
| EV/Revenue | -1.42 | -0.27 | -0.22 | -0.66 | -1.44 |
| ROE | -34.46% | 30.38% | 8.18% | 2.77% | 0.98% |
| ROA | -31.43% | 27.78% | 7.74% | 2.58% | 0.91% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short1,149,418
Change from Prior Settlement-14.39%
% of Float—
Days to Cover (Short Ratio)5.61
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-09-29; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Net profit margin is -256.6%. Finnhub fundamentals ↗
- Trailing 52-week price return is -25.0%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on KROS
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $32.0K | $14.1M | $18.2M | $211.2M | $0 | $0 | $0 |
| Operating income | -$30.9M | -$25.9M | -$15.4M | -$39.8M | $152.0M | -$58.7M | -$50.4M | -$48.5M |
| Net income | -$28.7M | -$23.7M | -$7.3M | -$30.7M | $148.5M | -$53.0M | -$45.3M | -$43.1M |
| EPS (diluted) | $-1.45 | $-1.21 | $-0.18 | $-0.76 | $3.62 | $-1.41 | $-1.25 | $-1.21 |
| EPS (basic) | $-1.45 | $-1.21 | $-0.18 | $-0.76 | $3.66 | $-1.41 | $-1.25 | $-1.21 |
| Operating margin | — | -$80.9K | -$109 | -$219 | $72 | — | — | — |
| Net margin | — | -$74.1K | -$52 | -$169 | $70 | — | — | — |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $287.6M | $312.3M | $338.0M | $742.8M | $757.2M | $784.6M | $615.9M | $579.3M |
| Total liabilities | $25.3M | $26.7M | $34.9M | $39.2M | $50.4M | $55.7M | $44.3M | $46.4M |
| Stockholders' equity | $262.3M | $285.6M | $303.1M | $703.6M | $706.7M | $728.9M | $571.6M | $532.8M |
| Total current assets | $266.9M | $290.7M | $315.4M | $719.3M | $732.8M | $759.5M | $588.9M | $552.0M |
| Total current liabilities | $12.2M | $12.9M | $20.4M | $24.1M | $34.7M | $39.4M | $27.4M | $29.0M |
| Cash & equivalents | $257.6M | $281.5M | $287.4M | $693.5M | $690.2M | $720.5M | $559.9M | $530.7M |
| Accounts receivable | $0 | $400.0K | $3.6M | $3.5M | $15.8M | $17.3M | $2.7M | $388.0K |
| Other current assets | $760.0K | $1.0M | $2.4M | $2.7M | $2.5M | $2.9M | $1.4M | $1.4M |
| Property, plant & equipment | $3.7M | $4.0M | $4.3M | $4.6M | $4.8M | $4.5M | $4.2M | $4.4M |
| Other non-current assets | — | — | $0 | $0 | $0 | $463.0K | $2.1M | $1.6M |
| Accounts payable | $1.8M | $1.5M | $2.0M | $2.3M | $5.3M | $6.6M | $4.6M | $5.0M |
| Accrued liabilities | $7.7M | $8.9M | $16.0M | $15.2M | $20.0M | $17.3M | $20.9M | $22.2M |
| Deferred revenue (current) | — | — | — | $155.0K | $925.0K | $3.3M | $0 | — |
| Other current liabilities | $482.0K | $88.0K | $217.0K | $212.0K | $349.0K | $532.0K | $416.0K | $354.0K |
| Other non-current liabilities | — | — | — | — | — | — | — | — |
| Common stock & paid-in capital | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K | $4.0K |
| Retained earnings | -$534.2M | -$505.5M | -$481.8M | -$458.3M | -$451.0M | -$420.3M | -$568.8M | -$522.8M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$20.4M | -$3.5M | -$27.3M | $3.2M | -$29.6M | $161.2M | -$46.0M | -$30.5M |
| Investing cash flow | -$155.0K | -$73.0K | -$134.0K | -$132.0K | -$720.0K | -$565.0K | -$289.0K | -$386.0K |
| Financing cash flow | -$3.3M | -$2.3M | -$378.6M | $140.0K | $17.0K | $4.0K | $75.5M | $155.9M |
| Free cash flow | -$20.6M | -$3.6M | -$27.4M | $3.1M | -$30.3M | $160.6M | -$46.3M | -$30.9M |
| Capital expenditures | $155.0K | $73.0K | $134.0K | $132.0K | $720.0K | $565.0K | $289.0K | $386.0K |
| Share-based compensation | $5.4M | $6.2M | $7.3M | $4.0M | $8.5M | $8.9M | $9.2M | $8.8M |
| Deferred income taxes | — | — | $0 | — | — | — | $0 | — |
| Change in accounts receivable | -$400.0K | -$3.2M | $75.0K | -$12.3M | -$1.5M | $14.5M | $2.4M | $384.0K |
| Change in accounts payable | $323.0K | -$108.0K | -$697.0K | -$3.0M | -$1.4M | $2.0M | -$293.0K | -$1.6M |
| Share repurchases | — | — | $375.0M | — | — | — | $0 | — |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Revenue | $243.9M | $0 | — | — | — |
| Operating income | $67.6M | -$210.8M | -$169.9M | -$114.8M | -$56.4M |
| Net income | $87.0M | -$187.4M | -$153.0M | -$104.7M | -$58.7M |
| EPS (diluted) | $2.30 | $-5.00 | $-5.20 | $-4.15 | $-2.52 |
| EPS (basic) | $2.34 | $-5.00 | $-5.20 | $-4.15 | $-2.52 |
| Operating margin | $28 | — | — | — | — |
| Net margin | $36 | — | — | — | — |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Total assets | $338.0M | $615.9M | $370.0M | $306.8M | $255.3M |
| Total liabilities | $34.9M | $44.3M | $37.8M | $29.4M | $12.1M |
| Stockholders' equity | $303.1M | $571.6M | $332.2M | $277.4M | $243.2M |
| Total current assets | $315.4M | $588.9M | $347.3M | $285.8M | $251.4M |
| Total current liabilities | $20.4M | $27.4M | $24.4M | $16.5M | $11.8M |
| Cash & equivalents | $287.4M | $559.9M | $331.1M | $279.0M | $230.0M |
| Accounts receivable | $3.6M | $2.7M | $143.0K | $0 | $18.0M |
| Other current assets | $2.4M | $1.4M | $1.0M | $276.0K | $210.0K |
| Property, plant & equipment | $4.3M | $4.2M | $4.1M | $2.0M | $1.3M |
| Other non-current assets | $0 | $2.1M | $2.1M | $2.1M | $82.0K |
| Accounts payable | $2.0M | $4.6M | $5.5M | $3.3M | $3.6M |
| Accrued liabilities | $16.0M | $20.9M | $17.9M | $12.8M | $7.3M |
| Other current liabilities | $217.0K | $416.0K | $665.0K | $750.0K | $204.0K |
| Other non-current liabilities | — | — | — | — | $0 |
| Common stock & paid-in capital | $4.0K | $4.0K | $3.0K | $2.0K | $2.0K |
| Retained earnings | -$481.8M | -$568.8M | -$381.4M | -$228.4M | -$123.8M |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | $107.5M | -$160.9M | -$124.5M | -$70.1M | -$62.1M |
| Investing cash flow | -$1.6M | -$1.9M | -$2.5M | -$1.2M | -$1.0M |
| Financing cash flow | -$378.5M | $391.8M | $179.0M | $120.3M | $28.6M |
| Free cash flow | $106.0M | -$162.8M | -$127.0M | -$71.3M | -$63.2M |
| Capital expenditures | $1.6M | $1.9M | $2.5M | $1.2M | $1.0M |
| Share-based compensation | $28.7M | $34.9M | $28.8M | $18.7M | $11.7M |
| Deferred income taxes | $0 | $0 | $0 | $0 | $0 |
| Change in accounts receivable | $825.0K | $2.6M | $143.0K | -$18.0M | $18.0M |
| Change in accounts payable | -$3.0M | -$249.0K | $1.6M | -$408.0K | $1.5M |
| Share repurchases | $375.0M | $0 | — | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding KROS as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2026-03-09 to 2026-08-18
Recent transactions
- Insiders have net sold 14,253 shares over the last 182 days, across 4 purchases and 8 sales.
- Most recent: Tanini Annita (Corp. Controller & VP, Finance) — Open market sale of 1,224 shares on 2026-08-18.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)4,000 sh(4 txns)
Sales (open market)18,253 sh(8 txns)
Net Shares-14,253
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Tanini Annita | Corp. Controller & VP, Finance | Open market sale | 2026-08-18 | 1,224 |
| Lerner Lorena Raquel | Chief Scientific Officer | Open market sale | 2026-08-18 | 3,568 |
| Cho Esther | Chief Legal Officer | Open market sale | 2026-08-18 | 4,485 |
| Newton Charles W. | Reporting person | Open market sale | 2026-08-18 | 551 |
| BIENAIME JEAN JACQUES | Reporting person | Open market purchase | 2026-08-17 | 1,000 |
| Prener Anne | Reporting person | Grant / award | 2026-07-01 | 13,786 |
| Farzan Nima | Reporting person | Open market sale | 2026-06-04 | 2,625 |
| Knowles Julius | Reporting person | Open market sale | 2026-06-04 | 2,625 |
| Seth Alpna | Reporting person | Open market sale | 2026-06-04 | 2,625 |
| GRAY MARY ANN | Reporting person | Grant / award | 2026-06-03 | 7,142 |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER | Option exercise | 2026-04-02 | 55,000 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-18 | Tanini Annita | Corp. Controller & VP, Finance | Open market sale | 1,224 | $10.29 |
| 2026-08-18 | Lerner Lorena Raquel | Chief Scientific Officer | Open market sale | 3,568 | $10.29 |
| 2026-08-18 | Cho Esther | Chief Legal Officer | Open market sale | 4,485 | $10.29 |
| 2026-08-18 | Newton Charles W. | Reporting person | Open market sale | 551 | $10.30 |
| 2026-08-17 | BIENAIME JEAN JACQUES | Reporting person | Open market purchase | 1,000 | $10.27 |
| 2026-07-15 | BIENAIME JEAN JACQUES | Reporting person | Open market purchase | 1,000 | $10.61 |
| 2026-07-01 | Prener Anne | Reporting person | Grant / award | 13,786 | $0.00 |
| 2026-06-15 | BIENAIME JEAN JACQUES | Reporting person | Open market purchase | 1,000 | $10.19 |
| 2026-06-11 | Newton Charles W. | Reporting person | Open market sale | 550 | $10.04 |
| 2026-06-04 | Farzan Nima | Reporting person | Open market sale | 2,625 | $10.73 |
| 2026-06-04 | Knowles Julius | Reporting person | Open market sale | 2,625 | $10.73 |
| 2026-06-04 | Seth Alpna | Reporting person | Open market sale | 2,625 | $10.72 |
| 2026-06-03 | Seth Alpna | Reporting person | Grant / award | 7,142 | $0.00 |
| 2026-06-03 | GRAY MARY ANN | Reporting person | Grant / award | 7,142 | $0.00 |
| 2026-06-03 | Farzan Nima | Reporting person | Grant / award | 7,142 | $0.00 |
| 2026-06-03 | BIENAIME JEAN JACQUES | Reporting person | Grant / award | 7,142 | $0.00 |
| 2026-06-03 | Knowles Julius | Reporting person | Grant / award | 7,142 | $0.00 |
| 2026-05-15 | BIENAIME JEAN JACQUES | Reporting person | Open market purchase | 1,000 | $10.58 |
| 2026-04-15 | BIENAIME JEAN JACQUES | Reporting person | Open market purchase | 1,000 | $11.70 |
| 2026-04-02 | Seehra Jasbir | CHIEF EXECUTIVE OFFICER | Option exercise | 55,000 | $0.30 |
| 2026-03-09 | Newton Charles W. | Reporting person | Grant / award | 13,215 | $0.00 |
| 2026-03-09 | BIENAIME JEAN JACQUES | Reporting person | Open market purchase | 2,000 | $11.21 |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 04:21 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-09-29 | 8-K | 2026-09-29 | View on SEC.gov → |
| 2026-09-28 | 8-K | 2026-09-28 | View on SEC.gov → |
| 2026-09-08 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-20 | 4 | 2026-08-18 | View on SEC.gov → |
| 2026-08-19 | 4 | 2026-08-17 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-08-03 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-03 | 8-K | 2026-08-03 | View on SEC.gov → |
| 2026-07-30 | 8-K | 2026-07-30 | View on SEC.gov → |
Recent news
Headlines about KROS (Keros Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Keros Therapeutics at Chardan conference: reset turns to pipeline data By Investing.com
Investing.com South Africa · 2026-10-20 -
A Phase 3 Win and a 130% Takeover Premium Lit Up Rare Blood-Disease Stocks on Monday
Yahoo · 2026-10-20 -
Keros Therapeutics Drops To US$10.66, Yet Insiders May Have Sold Too Early
Simply Wall Street · 2026-10-17 -
Keros Therapeutics Stock Price Forecast. Should You Buy KROS?
StockInvest.us · 2026-10-16 -
Can Reblozyl Power Bristol Myers' Top-Line Growth Going Forward?
Yahoo Finance · 2026-10-07 -
KROS Begins Dosing in Phase II Study With Rinvatercept in DMD
Yahoo Finance · 2026-09-29 -
Keros Therapeutics to Receive Additional Development Milestone Payment from Partner Takeda
Yahoo Finance · 2026-09-29 -
Keros Therapeutics Announces the First Patient Dosing in the Phase 2 Clinical Trial Evaluating Rinvatercept in DMD
Yahoo Finance · 2026-09-28
No headlines in this category right now — try “All”.